Notably, only partial responses to LSD1 inhibitors were seen in sensitive SCLC cell lines, which were attributed to TEAD4 activation–acquired resistance that could be alleviated with TEAD inhibitor cotreatment (113). The gene discussed is KDM1A; the disease is small cell lung carcinoma.